Nektar Therapeutics
General ticker "NKTR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $358.9M (TTM average)
Nektar Therapeutics follows the US Stock Market performance with the rate: 53.5%.
Estimated limits based on current volatility of 5.1%: low 33.89$, high 37.53$
Factors to consider:
- Total employees count: 61 (-55.5%) as of 2024
- US accounted for 1.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key drug candidates, Labor/talent shortage/retention, Supply chain disruptions, Operational and conduct risks, Cybersecurity threats
- Current price 187.0% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.09$, 22.06$]
- 2025-12-31 to 2026-12-31 estimated range: [3.94$, 13.13$]
Financial Metrics affecting the NKTR estimates:
- Negative: with PPE of -4.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -91.79 <= 0.04
- Negative: negative Net income
- Positive: 19.35 < Shareholder equity ratio, % of 19.99 <= 42.53
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 74.48 > -0.62
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Interest expense per share per price, % of 14.69 > 3.31
Short-term NKTR quotes
Long-term NKTR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $92.06MM | $90.12MM | $98.43MM |
| Operating Expenses | $468.22MM | $353.81MM | $203.62MM |
| Operating Income | $-376.17MM | $-263.68MM | $-105.20MM |
| Non-Operating Income | $11.18MM | $-12.57MM | $-14.00MM |
| Interest Expense | $28.91MM | $25.33MM | $28.11MM |
| R&D Expense | $218.32MM | $114.16MM | $120.91MM |
| Income(Loss) | $-364.98MM | $-276.26MM | $-119.20MM |
| Taxes | $3.21MM | $-0.20MM | $-0.24MM |
| Profit(Loss)* | $-368.20MM | $-276.06MM | $-118.96MM |
| Stockholders Equity | $366.64MM | $130.99MM | $60.74MM |
| Inventory | $19.20MM | $16.10MM | $0.00MM |
| Assets | $710.60MM | $398.03MM | $303.85MM |
| Operating Cash Flow | $-304.01MM | $-192.61MM | $-175.71MM |
| Capital expenditure | $5.68MM | $0.86MM | $1.47MM |
| Investing Cash Flow | $365.83MM | $139.56MM | $142.57MM |
| Financing Cash Flow | $1.51MM | $0.03MM | $42.12MM |
| Earnings Per Share** | $-29.51 | $-21.79 | $-8.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.